|Bid||3.050 x 100|
|Ask||3.200 x 200|
|Day's Range||3.050 - 3.250|
|52 Week Range||2.550 - 26.950|
|PE Ratio (TTM)||-1.42|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q2 2017 Cempra Inc Earnings and Update on the Merger with Melinta Therapeutics Inc Call
Melinta Therapeutics is buying a subsidiary of Chapel Hill-based Cempra that is expected to be publicly traded on the Nasdaq exchange. The new company will operate under Melinta’s name and Melinta will own 52 percent of the company with a majority control of the board of directors. The deal comes at a turbulent time for Cempra.
Melinta Therapeutics Inc. is merging with Cempra Inc., giving shareholders of the venture-backed antibiotics developer a majority stake in the resulting publicly traded company.